Form 4: Vigil Neuroscience Director Cheryl R. Blanchard Awarded Stock Options

Director Cheryl R. Blanchard received stock options for 18,068 shares of Vigil Neuroscience, Inc. on June 5, 2024.

Summary

• Cheryl R. Blanchard, a director of Vigil Neuroscience, Inc., was granted stock options to purchase 18,068 shares of common stock on June 5, 2024.
• The exercise price of the options is $3.38 per share.
• The options vest and become exercisable on the earlier of June 5, 2025, or the next annual meeting of the Issuer's stockholders.
• The options expire on June 5, 2034.
• The grant was made under the company's 2021 Stock Option and Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is a standard practice for director compensation.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. This grant is typical for directors of publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options as part of their director compensation plans.
• The vesting schedule of one year is fairly standard, aligning with typical industry practices.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates